Cargando…

Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial

BACKGROUND: No therapies have been proven to persistently improve the outcome of HTLV-I-associated myelopathy. Clinical benefit has been reported with zidovudine and with lamivudine in observational studies. We therefore conducted a randomised, double blind, placebo controlled study of six months co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taylor, Graham P, Goon, Peter, Furukawa, Yoshitaka, Green, Hannah, Barfield, Anna, Mosley, Angelina, Nose, Hirohisa, Babiker, Abdel, Rudge, Peter, Usuku, Koichiro, Osame, Mitsuhiro, Bangham, Charles RM, Weber, Jonathan N
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1590049/ https://www.ncbi.nlm.nih.gov/pubmed/16984654 http://dx.doi.org/10.1186/1742-4690-3-63

Ejemplares similares

Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus
por: Cong, Yu, et al.
Publicado: (2016)

Quantification of the virus-host interaction in human T lymphotropic virus I infection
por: Asquith, Becca, et al.
Publicado: (2005)

Zidovudine/Lamivudine for HIV-1 Infection Contributes to Limb Fat Loss
por: van Vonderen, Marit G. A., et al.
Publicado: (2009)

Quality by Design Optimization of Cold Sonochemical Synthesis of Zidovudine-Lamivudine Nanosuspensions
por: Witika, Bwalya A., et al.
Publicado: (2020)

Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand
Publicado: (2016)

Lamivudine and Zidovudine-Loaded Nanostructures: Green Chemistry Preparation for Pediatric Oral Administration
por: Guedes, Marina D. V., et al.
Publicado: (2023)

The NRTIs Lamivudine, Stavudine and Zidovudine Have Reduced HIV-1 Inhibitory Activity in Astrocytes
por: Gray, Lachlan R., et al.
Publicado: (2013)

Intrinsic Replication Competences of HIV Strains After Zidovudine/Lamivudine/Nevirapine Treatment in the Philippines
por: Kageyama, Seiji, et al.
Publicado: (2019)

Clinical, Immunological and Virological Responses of Zidovudine-Lamivudine-Nevirapine versus Zidovudine-Lamivudine-Efavirenz Antiretroviral Treatment (ART) Among HIV-1 Infected Children: Asella Teaching and Referral Hospital, South-East Ethiopia
por: Sorsa, Abebe
Publicado: (2018)

Haematological and molecular responses in patients with chronic ATLL treated with zidovudine and interferon-α
por: Hodson, Andrew, et al.
Publicado: (2014)

Brain antioxidants and hippocampal microanatomical alterations following the administration of Efavirenz/Lamivudine/Tenofovir disoproxil fumarate and Lamivudine/Nevirapine/Zidovudine in adult male Wistar rats
por: Edagha, Innocent A., et al.
Publicado: (2022)

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)
por: Kumar, Princy N, et al.
Publicado: (2009)

Parkinsonism in a Patient with Human T-lymphotropic Virus 1 Myelopathy
por: Afzal, Hasnain, et al.
Publicado: (2018)

Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis
por: Alzate Angel, Juan Carlos, et al.
Publicado: (2017)

Zidovudine.
por: Sperling, R
Publicado: (1998)

Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data
por: Rodriguez, Allan E, et al.
Publicado: (2010)

Development and validation of a normal-phase HPTLC method for the simultaneous analysis of Lamivudine and Zidovudine in fixed-dose combination tablets
por: Venkatesh, Palani, et al.
Publicado: (2012)

Pharmacokinetics of lamivudine, abacavir and zidovudine administered twice daily as syrups versus scored tablets in HIV-1-infected Ugandan children
por: Gitta, PK, et al.
Publicado: (2010)

Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir
por: Ross, L. L., et al.
Publicado: (2010)

A Caucasian Australian presenting with human T-lymphotropic virus type I associated myelopathy: a case report
por: Faull, Matthew, et al.
Publicado: (2014)

Physiotherapy for human T-lymphotropic virus 1-associated myelopathy: review of the literature and future perspectives
por: Sá, Katia N, et al.
Publicado: (2015)

Neuroimmunology of Human T-Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis
por: Nozuma, Satoshi, et al.
Publicado: (2019)

Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus‐1 associated myelopathy
por: Matsuo, Tomohiro, et al.
Publicado: (2018)

KIR2DL2 Enhances Protective and Detrimental HLA Class I-Mediated Immunity in Chronic Viral Infection
por: Seich al Basatena, Nafisa-Katrin, et al.
Publicado: (2011)

A proof of concept study of Infliximab for the treatment of HTLV-1-associated myelopathy
por: Martin, Fabiola, et al.
Publicado: (2014)

Zidovudine-induced myopathy
por: Wiwanitkit, Viroj
Publicado: (2011)

Zidovudine Induced Hyperpigmentation
por: Premjith, Raveendran, et al.
Publicado: (2022)

Clinical Pathophysiology of Human T-Lymphotropic Virus-Type 1-Associated Myelopathy/Tropical Spastic Paraparesis
por: Yamano, Yoshihisa, et al.
Publicado: (2012)

Human T-cell lymphotropic virus, type 1 (HTLV-1)-associated myelopathy: MR findings
por: Petscavage, Jonelle M., et al.
Publicado: (2015)

Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092
por: Owor, Maxensia, et al.
Publicado: (2021)

Human T-Lymphotropic Virus-1 Visualized at the Virological Synapse by Electron Tomography
por: Majorovits, Endre, et al.
Publicado: (2008)

Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA)
Publicado: (2008)

Signs, meanings and practices of people living with human t-cell lymphotropic virus type 1 or tropical spastic myelopathy
por: Santana, Genildes Oliveira, et al.
Publicado: (2020)

First line treatment of acute and chronic ATLL with zidovudine (AZT) and interferon alpha (IFN-α): haematological and molecular responses
por: Hodson, Andrew, et al.
Publicado: (2011)

Placental Transport of Zidovudine in the Rhesus Monkey
por: Ridgway III, Louis E., et al.
Publicado: (1993)

Plasma proteome analysis in HTLV-1-associated myelopathy/tropical spastic paraparesis
por: Kirk, Paul DW, et al.
Publicado: (2011)

Electrophysiological Analysis Shows Dizziness as the First Symptom in Human T Cell Lymphotropic Virus Type-Associated Myelopathy/Tropical Spastic Paraparesis
por: Labanca, Ludimila, et al.
Publicado: (2015)

Effect of pulsed methylprednisolone on disease severity, viral load and inflammation in patients with human T-lymphotropic virus type 1 associated myelopathy
por: Buell, Kevin, et al.
Publicado: (2015)

Human T-Lymphotropic Virus-1–Associated Myelopathy/Tropical Spastic Paraparesis Is Associated With Sexual Dysfunction in Infected Women of Reproductive Age
por: Lopes Martins, Adenilda Lima, et al.
Publicado: (2018)

Editorial Commentary: Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) and HTLV-1–Associated Myelopathy/Tropical Spastic Paraparesis
por: Taylor, Graham P.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_f8ekimiq8gv6ouakdv1f4pr8t0